Edition:
India

ANI Pharmaceuticals Inc (ANIP.OQ)

ANIP.OQ on NASDAQ Stock Exchange Global Market

64.45USD
1:30am IST
Change (% chg)

$1.14 (+1.80%)
Prev Close
$63.31
Open
$63.20
Day's High
$65.51
Day's Low
$63.20
Volume
33,978
Avg. Vol
23,889
52-wk High
$72.81
52-wk Low
$39.83

Latest Key Developments (Source: Significant Developments)

ANI Pharmaceuticals Reports Q4 and FY2018 Results, Provides 2019 Guidance
Wednesday, 27 Feb 2019 

Feb 27 (Reuters) - ANI Pharmaceuticals Inc ::ANI PHARMACEUTICALS REPORTS RECORD FULL YEAR AND FOURTH QUARTER 2018 RESULTS AND PROVIDES 2019 GUIDANCE.Q4 REVENUE $57.1 MILLION VERSUS REFINITIV IBES ESTIMATE OF $53.5 MILLION.Q4 ADJUSTED NON-GAAP EARNINGS PER SHARE $5.07.Q4 GAAP EARNINGS PER SHARE $1.30.Q4 EARNINGS PER SHARE ESTIMATE $1.24 -- REFINITIV IBES DATA.SEES 2019 NET REVENUES OF $231 MILLION TO $245 MILLION.SEES 2019 ADJUSTED NON-GAAP EBITDA OF $95 MILLION TO $105 MILLION.SEES 2019 ADJUSTED NON-GAAP DILUTED EARNINGS PER SHARE OF $5.57 TO $6.21.FY2019 EARNINGS PER SHARE VIEW $5.79, REVENUE VIEW $243.4 MILLION -- REFINITIV IBES DATA.  Full Article

ANI Pharmaceuticals Q4 Adjusted Non-GAAP Earnings Per Share $1.32
Wednesday, 27 Feb 2019 

Feb 27 (Reuters) - ANI Pharmaceuticals Inc ::ANI PHARMACEUTICALS REPORTS RECORD FULL YEAR AND FOURTH QUARTER 2018 RESULTS AND PROVIDES 2019 GUIDANCE.Q4 REVENUE $57.1 MILLION VERSUS REFINITIV IBES ESTIMATE OF $53.5 MILLION.Q4 ADJUSTED NON-GAAP EARNINGS PER SHARE $1.32.Q4 GAAP EARNINGS PER SHARE $0.46.Q4 EARNINGS PER SHARE ESTIMATE $1.24 -- REFINITIV IBES DATA.SEES 2019 NET REVENUES OF $231 MILLION TO $245 MILLION.SEES 2019 ADJUSTED NON-GAAP EBITDA OF $95 MILLION TO $105 MILLION.SEES 2019 ADJUSTED NON-GAAP DILUTED EARNINGS PER SHARE OF $5.57 TO $6.21.FY2019 EARNINGS PER SHARE VIEW $5.79, REVENUE VIEW $243.4 MILLION -- REFINITIV IBES DATA.  Full Article

Ani Pharmaceuticals To Repurchase $25 Mln Aggregate Principal Amount Of Notes
Friday, 7 Dec 2018 

Dec 7 (Reuters) - ANI Pharmaceuticals Inc ::ANI PHARMACEUTICALS ENTERS INTO SEPARATE PRIVATELY NEGOTIATED AGREEMENTS WITH CERTAIN HOLDERS OF ITS CONVERTIBLE NOTES.ANI PHARMACEUTICALS-ENTERED INTO SEPARATE, PRIVATELY NEGOTIATED AGREEMENTS WITH CERTAIN HOLDERS OF OUTSTANDING 3.00% CONVERTIBLE SENIOR NOTES DUE 2019.ANI PHARMACEUTICALS INC - AGREED TO REPURCHASE $25.0 MILLION AGGREGATE PRINCIPAL AMOUNT OF NOTES FOR A TOTAL OF $26.1 MILLION IN CASH.ANI PHARMACEUTICALS INC - ANI HAS ALSO ENTERED INTO AN AGREEMENT WITH DEALER PARTY TO CERTAIN CONVERTIBLE NOTE HEDGE TRANSACTIONS.ANI PHARMACEUTICALS INC - ALSO ENTERED INTO AGREEMENTS WITH SUCH DEALER COUNTERPARTY TO UNWIND CERTAIN WARRANT TRANSACTIONS.  Full Article

ANI Pharmaceuticals Announces Approval Of Morphine Sulfate Oral Solution
Wednesday, 18 Apr 2018 

April 18 (Reuters) - ANI Pharmaceuticals Inc ::ANI PHARMACEUTICALS ANNOUNCES APPROVAL OF MORPHINE SULFATE ORAL SOLUTION.ANI PHARMACEUTICALS INC - RECEIVED APPROVAL FROM U.S. FDA OF ITS ANDA FOR MORPHINE SULFATE ORAL SOLUTION 10MG/5ML, 20MG/5ML AND 100MG/5ML.  Full Article

Ani Pharmaceuticals Enters Five-Year $125 Mln Senior Secured Credit Facility With Citizens Bank
Friday, 29 Dec 2017 

Dec 29 (Reuters) - Ani Pharmaceuticals Inc ::ANI PHARMACEUTICALS ENTERS FIVE-YEAR $125 MILLION SENIOR SECURED CREDIT FACILITY WITH CITIZENS BANK.ANI PHARMACEUTICALS SAYS FACILITY ALSO INCLUDES A $50 MILLION SENIOR SECURED REVOLVING CREDIT FACILITY WHICH REMAINS UN-DRAWN.ANI PHARMA SAYS TERM LOAN ALSO USED TO REFINANCE EXISTING INDEBTEDNESS OF $25 MILLION.  Full Article

Ani Pharmaceuticals Acquires Four NDAs From AstraZeneca For $46.5 Mln
Friday, 29 Dec 2017 

Dec 29 (Reuters) - Ani Pharmaceuticals Inc ::ANI PHARMACEUTICALS ACQUIRES FOUR NDAS FROM ASTRAZENECA FOR $46.5 MILLION.ANI PHARMACEUTICALS INC - ACQUISITIONS WERE FUNDED THROUGH A COMBINATION OF CASH AND DEBT.ANI PHARMACEUTICALS SAYS ADDITION OF ASSETS WILL BE MATERIAL TO REVENUE AND EBITDA IN 2018.  Full Article

ANI Pharmaceuticals Q3 gaap earnings per share $0.40
Thursday, 2 Nov 2017 

Nov 2 (Reuters) - ANI Pharmaceuticals Inc :ANI Pharmaceuticals reports record third quarter and year-to-date 2017 results and narrows full year guidance.Q3 adjusted Non-GAAP earnings per share $1.11.Q3 GAAP earnings per share $0.40.Q3 revenue $48.2 million versus I/B/E/S view $48.1 million.Q3 earnings per share view $0.99 -- Thomson Reuters I/B/E/S.ANI Pharmaceuticals Inc sees ‍for full year 2017 net revenues $181 million to $183 million​.ANI Pharmaceuticals Inc sees ‍for full year 2017 adjusted Non-GAAP diluted earnings per share $3.83 to $4.00​.Q3 earnings per share view $0.99, revenue view $48.1 million -- Thomson Reuters I/B/E/S.FY2017 earnings per share view $3.84, revenue view $182.1 million -- Thomson Reuters I/B/E/S.ANI Pharmaceuticals Inc - ‍ANI intends to request a meeting with fda in Q4 of 2017 to present its regulatory filing plan​.  Full Article